Patient preferences for endpoints in fecal incontinence treatment studies by Heymen, S. et al.
Patient preferences for endpoints in fecal incontinence 
treatment studies































of	 treatment	should	be	defined,	77%	said	by	a	 reduction	 in	 frequency	or	complete	





58%	overall	but	only	26%	for	 those	aged	≥65.	 “Adequate	relief”	was	acceptable	 to	
78%.












only	 one-	third	 of	 those	 affected	 receive	 medical	 evaluation	 and	
treatment.7


















Incontinence	 Severity	 Index	 11	 while	 others	 used	 the	 Cleveland	
Clinic	 scale	 17	 or	 the	 Vaizey	 scale.13,18	 (Involuntary	 loss	 of	 gas	 is	
scored	as	FI	on	all	 three	of	 these	 scales.)	Patient	 reports	of	 “ade-
quate	relief”	from	fecal	incontinence	11	or	global	ratings	of	symptom	
improvement	12	were	the	primary	endpoints	in	other	trials.	Recently	
published	 studies,	 on	 the	 basis	 of	which	 the	U.S.	 Food	 and	Drug	
Administration	(FDA)	approved	new	treatments	for	FI,	defined	a	re-

















The	 FDA	 recommends	 that	 outcome	 measures	 for	 functional	
gastrointestinal	 and	 motility	 disorders	 should	 be	 patient-	reported	
outcomes	 that	 are	 developed	 with	 input	 from	 focus	 groups.22 
However,	 up	 to	 now	none	 of	 the	 case	 definitions	 or	 primary	 out-
come	measures	used	 in	pivotal	RCTs	 to	evaluate	 the	effectiveness	
of	treatments	for	FI	were	developed	with	 input	from	patients.	The	
development	 and	validation	of	 patient-	based	FI	 severity	measures	







quency	by	at	 least	50%,	and	adequate	 relief	of	FI;	 (iii)	 to	determine	




2  | MATERIALS AND METHODS













Hill	 (UNC),	 and	 a	 research	 participant	 registry	 maintained	 by	 the	
UNC	Center	 for	 Functional	Gastrointestinal	 and	Motility	Disorders.	
Prospective	participants	first	logged	onto	a	website	to	give	informed	
consent	 and	 answered	 standardized	 questionnaires	 on	 FI	 sever-
ity	 (Fecal	 Incontinence	 Severity	 Index,24	 Fecal	 Incontinence	 and	






the	 topics	 to	be	 covered	 in	 these	 two-	hour	 sessions	would	 include	
(i) how	FI	should	be	defined,	and	(ii)	what	is	the	best	way	to	measure
success	when	 treating	 bowel	 leakage.	Open-	ended	 questions	were
combined	 with	 more	 structured	 probes	 as	 shown	 in	 Table	1.	 The
initial	 set	of	prompts	were	 selected	based	on	a	 review	of	outcome
Key Points
• None	of	the	current	case	definitions	or	primary	outcome
measures	 used	 to	 evaluate	 the	 effectiveness	 of	 treat-
ments	 for	 fecal	 incontinence	 (FI)	 were	 developed	 with
input	 from	 patients.	Using	 focus	 groups	 and	 a	 national


















































will	 be	 reported	 in	 a	 separate	 publication.)	 Two	 questions	 from	 an	
early	part	of	the	questionnaire	were	repeated	unexpectedly	towards	
the	end	of	the	survey	as	a	check	on	data	quality,	and	subjects	whose	






















































endpoints.	 The	 independent	 variables	 included	 in	 these	 regression	





Both	 phases	 of	 this	 study	were	 reviewed	 and	 approved	 by	 the	
Institutional	Review	Committee	for	the	Protection	of	Human	Research	
Participants	at	the	University	of	North	Carolina.	Phase	2	of	the	study	





ing	 in	 age	 from	21	 to	87	years.	To	 reassure	participants	 about	 their	















answered	 “yes”	 to	 consistency	 of	 stool	 loss	 (82.1%)	 and	 frequency	
of	FI	(57.1%);	however,	only	42.9%	indicated	that	embarrassment	or	
bother	should	be	included	in	the	definition	and	37%	said	volume	of	
stool	 lost	 should	be	 included.	When	 these	 focus	group	participants	
were	asked	to	rate	the	importance	of	these	four	characteristics	plus	








sistency	 (P=.004),	 and	 bothersomeness	 (P=.047)	 but	 not	 compared	
to	 intestinal	 discomfort	 (P>.05	 for	 both).	None	of	 the	other	 ratings	
made	 by	 focus	 group	 participants	 were	 significantly	 different	 from	
each	other.

































Rating of Importance to Definition of FI 
on 0- 10 Scale (Mean±95% CI)
Phase 1: Focus 
groups 
















Table	5,	 acceptability	 of	 this	 endpoint	 varied	 greatly	 as	 a	 function	
of	FI	severity,	impact	of	FI	on	quality	of	life,	and	demographic	char-
acteristics.	When	 FISI	 total	 severity	 scores	were	 divided	 into	 ter-
tiles,	the	third	of	participants	with	the	most	severe	FI	were	2.4	times	
more	 likely	 than	 those	with	 the	mildest	 FI	 severity	 to	 be	 satisfied	
























ment	 success	 vs	 those	 who	 were	 not	 satisfied	 with	 this	 endpoint	
(χ2=83.96,	P<.001,	df=12).	Nagelkerke’s	R2	of	 .504	 indicated	a	mod-
est	relationship	between	the	predictors	and	the	dependent	measure.	
Overall	 prediction	 success	 was	 78.2%.	 The	Wald	 criterion	 demon-
strated	 that	 the	 significant	 independent	predictors	were	of	younger	







compared	 the	 distribution	 of	 responses	 to	 Question	 2,	 (how	much	
improvement	is	necessary	for	treatment	to	be	considered	successful)	







ple	with	FI	was	asked	 to	 rate	 the	 importance	of	 the	same	six	char-
acteristics	 for	 defining	 FI	 that	 the	 focus	 group	 participants	 rated	
(Table	3).	Frequency	and	urgency	were	rated	the	most	 important	to	












































3.2.3 | Defining a treatment responder by a report of 
Adequate Relief of FI
When	 participants	 were	 asked	 whether	 “adequate	 relief”	 of	
FI	 would	 be	 acceptable	 for	 identifying	 treatment	 responders,	
145/186	(78%)	said	“yes”.	Demographic	variables	that	were	found	
in	 univariate	 statistical	 tests	 to	 be	 significantly	 associated	 with	




Table	5,	 the	 acceptability	 of	 “adequate	 relief”	 as	 a	 trial	 endpoint	
was	related	to	the	severity	of	FI:	The	third	of	participants	with	the	
most	severe	FISI	scores	were	1.4	times	more	likely	to	find	adequate	
TABLE  5   Patient	characteristics	that	moderate	the	acceptability	of	different	outcome	measures
Possible moderator
Responder defined by  
≥50% less FI (%)
Responder defined by 
adequate relief of FI (%)
How much decrease is required 
for treatment success? (%)
Sex
Female 45 68 77
Male 71a 77a 77
Age	ranges
Age	18-	34	years 80 92 70
Age	35-	64	years 60a,c 83c 80a
Age	≥65	years 26a,b 50a,b 79a
Race
White 55 77 77
Black 40 67c 80
Hispanic	(any	race) 94a,b 100a,b 72
Education
High	School	or	less 44 59 79
College 47c 78a 76
Post-	graduate 75a,b 85a 78
Family	income
<$35	000 42 65 77
$35	000-	$75	000 38c 76c 78
>$75	000 86a,b 93a,b 76
Marital	status
Married	or	cohabiting 63 84 78
Single,	widowed,	divorced 49 68a 75
Consulter	for	FI
Consulted	MD	for	FI 39 67 77
Did	not	consult	for	FI 73a 86a 77
FI	severity	(FISI	score)
FISI	<18	(mildest	tertile) 38 70 78
FISI	19-	38	(middle) 43c 69c 76
FISI	>39	(most	severe) 92a,b 95a,b 78
FIQOL	Total	Score
Most	affected	tertile 87 95 78
Intermediate 46a 72a 76
Least	affected 40a 67a 78
Volume	of	stool	loss
Small	amount	(staining) 42 72 76
Moderate	amount 45c 67c 76
Large	amount	(full	BM) 88a,b 95a,b 80
Superscripts:	aSignificantly	different	from	row	A;	bSignificantly	different	from	row	B;	cSignificantly	different	from	row	C.











Nagelkerke’s	R2	of	 .332	 indicated	a	weak	but	 statistically	 significant	
relationship	 between	 the	 predictors	 and	 the	 dependent	 measure.	
Overall	 prediction	 success	 was	 79.9%.	 The	Wald	 criterion	 demon-




3.2.4 | How much reduction in FI frequency is 
enough?
When	survey	participants	were	asked	to	rate	how	much	reduction	
in	 FI	would	 be	 required	 before	 they	 considered	 a	 treatment	 suc-
cessful,	 the	average	amount	of	 reduction	 required	was	77%,	with	
a	95%	confidence	interval	of	75%-	80%.	The	response	scale	was	in	















(including	 some	 non-	patients	with	 FI)	 to	 confirm	 and	 elaborate	 the	
focus	group	findings.	While	one	other	study27	has	used	focus	groups	
of	patients	with	FI	to	address	the	definition	of	FI	and	trial	endpoints,	
the	methods	used	differed	 from	ours,	 and	so	did	many	of	 the	find-
ings:	Sung	and	colleagues	began	with	a	systematic	review	of	the	lit-
erature	to	develop	a	conceptual	framework	describing	how	patients	
think	 about	 FI.	 They	used	 this	 framework	 to	 guide	 their	 interviews	
with	patients,	 and	 the	 comments	of	patients	 confirmed	 the	a	priori	
















“Intestinal	 discomfort”	 was	 queried	 in	 both	 Phase	 1	 and	 Phase	






50% Decrease in FI Adequate Relief
















However,	 this	 is	 an	 ambiguous	 term.	We	 did	 not	 include	 questions	
to	clarify	its	meaning	because	its	mention	by	patients	in	Phase	1	was	
unanticipated,	 and	 because	 we	 wanted	 the	 two	 surveys	 to	 reflect	


































When	 we	 compared	 the	 responses	 of	 subjects	 in	 the	 national	
survey	 to	 a	 yes/no	 question	 about	whether	 a	 50%	 reduction	 in	 FI	
frequency	was	an	acceptable	measure	of	success	in	a	clinical	trial	to	




the	 study	design.	However,	many	 subjects	who	answered	 that	 they	
were	willing	 to	 accept	 a	50%	decrease	as	 a	meaningful	 endpoint	 in	
a	 clinical	 trial	would	nevertheless	prefer	 a	 larger	decrease	 in	FI	 fre-









not	 significantly	 influenced	by	 these	demographic	variables	or	mea-
sures	of	FI	severity	and	quality	of	life	impact.
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A	 recent	 reanalysis	 28	 of	 the	 data	 from	 the	 dextranomer	 trial	 10 
showed	 that	 a	 50%	 reduction	 in	 FI	 episodes	was	 significantly	 cor-
related	with	improvements	in	the	Cleveland	Clinic	Fecal	Incontinence	
Score,29	 the	 Fecal	 Incontinence	Quality	 of	 Life	 scale,26	 and	 several	
diary-	based	measures	 of	 fecal	 incontinence.	The	authors	 concluded	
that	the	responder	definition	based	on	a	50%	decrease	in	FI	episodes	










We	 also	 assessed	 satisfaction	with	 a	 second	 endpoint	 that	 has	
been	used	in	biofeedback	trials,11	namely	“adequate	relief	of	FI”.	This	



































4.3 | Should decisions about the success of 













the	mechanism	 of	 action	 of	 the	 investigational	 intervention.	 These	
symptoms	 should	 also	 be	 incorporated	 into	multicomponent	meas-
ures	of	FI	severity.
Several	 questionnaires	 5,24,29–33	 have	 been	 developed	 and	vali-
dated	for	the	measurement	of	FI	severity	which	attempt	to	capture	












they	 are	 not	 easily	 translated	 into	 clinically	meaningful	 differences	
between	patients.23,34	Our	suggestion	that	 the	primary	outcome	 in	
RCTs	 for	 treatment	of	FI	 should	be	based	on	 a	≥75%	 reduction	 in	
FI	frequency	is	simple,	straightforward	in	 its	 interpretation,	reflects	
patient	 preferences,	 and	 is	 consistent	 with	 the	 outcome	 measure	




the	 interpretation	of	 recently	published	randomized	controlled	 trials	































apeutic	 outcome.	The	 survey	 sample,	while	 nationally	 representative	
and	unselected	with	respect	to	prior	knowledge	of	what	the	survey	was	
about,	nevertheless	contained	more	subjects	with	post-	baccalaureate	
















with	 treatments	 that	 are	 FDA	 approved	 but	 that	 produce	 relatively	
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